Product Pathways - Growth Factors/Cytokines
Mouse His6Interleukin-6 (mHis6IL-6) #8857
|8857SC||10 µg (With Carrier)||---||In Stock||---|
|8857SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse His6IL-6 (mHis6IL-6) Phe25-Thr211 (Accession #NP_112445) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant N-terminally His6-tagged mIL-6 has a calculated MW of 24,311. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant mHis6IL-6 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mHis6IL-6. All lots are greater than 98% pure.
The bioactivity of recombinant mIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 and 5 pg/ml.
The purity of recombinant mHis6IL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mHis6IL-6 and staining overnight with Coomassie Blue.
The ability of mHis6IL-6 to induce phosphorylation of Stat3 was assessed. B9 cells were treated with increasing concentrations of mHis6IL-6 for 10 min. Cells were lysed, and phospho-Stat3 was quantified using PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA Kit #7300. OD450 is shown.
The proliferation of B9 cells treated with increasing concentrations of mHis6IL-6 was assessed. After 48 hr treatment with mHis6IL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Less than 0.01 ng endotoxin/1 μg mHis6IL-6.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mHis6IL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial, and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, among others. IL-6 in concert with TGF-β is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/MAPK (Erk) cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3). This IL-6/soluble IL-6Rα complex can activate the gp130 signaling pathway on cells that express gp130, but not IL-6Rα (3). Research studies have shown that IL-6 may contribute to metastatic breast cancer by increasing expression of proangiogenic VEGF (5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
PathScan® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.